What if we had the same tools for diagnosis and treatment for retinopathy and retinoid-related vision loss?
This would mean a faster diagnosis, a lower treatment cost, and more efficient treatment.
In the past few years, a number of companies have demonstrated that they can build on the existing evidence base and bring a better treatment to patients who have not yet been diagnosed.
We are now seeing a number that have shown promise in the field of retinotherapy.
Here we look at three of them.